Form 4: Aclaris Therapeutics Director Leonard Michael Braden Acquires Additional Shares

Director Leonard Michael Braden reports acquisition of Aclaris Therapeutics shares through BML Investment Partners, L.P.

Summary

• On July 18, 2024, Leonard Michael Braden, a director of Aclaris Therapeutics, Inc., acquired 130,317 shares of common stock at a weighted average price of $1.3011 per share.
• On July 19, 2024, Braden acquired an additional 6,689 shares at a weighted average price of $1.30 per share.
• On July 22, 2024, Braden acquired 17,716 shares at a weighted average price of $1.3297 per share.
• These transactions were made through BML Investment Partners, L.P., where BML Capital Management, LLC serves as the general partner and Mr. Leonard is the managing member.
• Following these transactions, Mr. Leonard is deemed to beneficially own 13,602,691 shares through his indirect ownership via BML Investment Partners, L.P.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as insider buying can be interpreted as a sign of confidence, but it's a routine transaction.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that those with the most knowledge of the company believe its stock is undervalued or that positive developments are on the horizon.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive signal.

Key Dates